Tvardi Therapeutics, Inc. (TVRD) fundamentals score
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 6.9 out of 10, Mixed fundamentals
- Growth: 4.8/10
- Profitability: 7.0/10
- Financial health: 8.1/10
- Earnings quality: 10.0/10
- Valuation: 5.8/10
Scores are calculated from Tvardi Therapeutics, Inc.’s SEC filings, using the 12 months through 2025-03. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10